Early Detection of Cognitive Dysfunction in Diabetes

Dementia Clinical Trial

Official title:

Study of Cognitive Dysfunction and Diabetes

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01830998
• Other study ID #: 20130401
• Status: Recruiting
• Phase: N/A
• First received: April 1, 2013
• Last updated: December 9, 2014
• Start date: January 2012
• Est. completion date: December 2014

Study information

• Verified date: December 2014
• Source: Wuhan General Hospital of Guangzhou Military Command
• Contact: xuzhipeng Wuqiang lihonghua, doctor
• Phone: 13871168392
• Email: 21823074[@]qq.com
• Is FDA regulated: No
• Health authority: China: Food and Drug Administration
• Study type: Observational

Clinical Trial Summary

The rate of cognitive decline due to ageing is increased 1.5-fold to 2.0-fold in individuals with type 2 diabetes.There are no established specific treatment measures to prevent or ameliorate cognitive impairments in patients with diabetes. we want to detecte early clinical dementia in diabete.

Description:

Clinically relevant cognitive decrements in relation to diabetes mainly occur during two crucial periods in life: the period of brain development in childhood, and the period when the brain undergoes neurodegenerative changes associated with ageing.Potential leads for treatment are to optimise glycaemic control and avoid and treat vascular risk factors.we want to detecte early clinical dementia in diabete by MMSE and Olfactory function.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 400
• Est. completion date: December 2014
• Est. primary completion date: December 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 50 Years to 80 Years

Eligibility

Inclusion Criteria:

• Patients with type 2 diabetes(Age>50 years)

Exclusion Criteria:

• with stroke or other complications.

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

• Cognition Disorders
• Dementia
• DM
• MCI

Locations

Country	Name	City	State
China	tongji Medical University	Wuhan	Hubei
China	Wuhan general hospital of Guangzhou Command	Wuhan	Hubei
China	Wuhan general hospital of Guangzhou command	Wuhan,chongqing	Hubei

Sponsors (1)

Lead Sponsor	Collaborator
Wuhan General Hospital of Guangzhou Military Command

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	MMSE Olfactory function dementia	MMSE,Olfactory function and PET(fMRI) were observed.	2 years	Yes